On December 16, 2025, NetraMark Holdings Inc., an innovative artificial intelligence (AI) firm, announced its collaboration with the Centre for Addiction and Mental Health (CAMH) in Toronto. This partnership has been awarded the prestigious Ontario Research Fund – Research Excellence (ORF-RE) Award, aimed at advancing research in the field of mental health, specifically focusing on schizophrenia and major depressive disorders.
The collaboration will utilize NetraAI, NetraMark’s advanced machine learning platform, to analyze genetic and epigenetic data derived from studies supported by the ORF-RE program. This effort seeks to identify specific patient subpopulations that clarify biological subtypes in psychiatric disorders, ultimately enhancing precision treatment strategies.
Enhancing Clinical Trial Outcomes
As part of this initiative, the installation of NetraAI will take place within CAMH’s secure high-performance computing environment, with the support of CAMH’s Research IT team and NetraMark staff. All analyses conducted will use de-identified patient data, maintaining compliance with CAMH’s stringent data privacy and security protocols.
Dr. James Kennedy, head of the Tanenbaum Centre for Pharmacogenetics at CAMH, emphasized the significance of this collaboration. He stated, “This collaboration integrates NetraMark’s unique AI approach with CAMH’s deep genomic and clinical datasets to explore how genetic and epigenetic patterns influence treatment response. The insights generated will advance our understanding of the genes that alter a patient’s response to psychiatric medication.”
Dr. Joseph Geraci, founder and Chief Scientific & Technology Officer of NetraMark, expressed pride in the collaboration, noting that it allows for the exploration of biologically grounded subpopulations that traditional analytics may overlook. He remarked, “We believe this work will contribute to next-generation precision-medicine approaches for mental health and improve clinical trial outcomes.”
Evaluation of Broader Health Impacts
Additionally, this partnership will evaluate a “bonus dataset” from the Ontario Health Insurance Plan (OHIP) to conduct cost-effectiveness analyses. This exploration aims to assess the broader implications of personalized patient care on the healthcare system.
CAMH stands as Canada’s largest mental health and addiction teaching hospital, recognized globally for its leadership in psychiatric research. The centre integrates clinical care, research, education, policy development, and health promotion to support individuals affected by mental illness and addiction.
NetraMark is committed to leading the development of generative artificial intelligence and machine learning solutions for the pharmaceutical industry. Its unique topology-based algorithm can parse patient data into related subsets, enabling more effective data analysis and enhancing clinical trial methodologies.
This collaboration marks a significant step forward in the intersection of AI technology and mental health research, potentially leading to improved treatment outcomes for patients dealing with complex mental health conditions.
